(1 R)-2-[(4-aminophenethyl)amino]-1-(3-pyridinyl)-1-ethanol | 173901-04-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1 R)-2-[(4-aminophenethyl)amino]-1-(3-pyridinyl)-1-ethanol
• 英文别名: (I+/-R)-I+/--[[[2-(4-Aminophenyl)ethyl]amino]methyl]-3-pyridinemethanol；(1R)-2-[2-(4-aminophenyl)ethylamino]-1-pyridin-3-ylethanol
• CAS: 173901-04-7
• 化学式: C₁₅H₁₉N₃O
• 分子量: 257.335
• InChiKey: VNQJQZZPHBWMLG-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  71.2
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1 R)-2-[(4-aminophenethyl)amino]-1-(3-pyridinyl)-1-ethanol 在 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Malamas; Largis; Gunawan, Medicinal Chemistry Research, 2000, vol. 10, # 3, p. 164 - 177

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(4-氨基苯)乙胺 、 2-(2-环氧乙烷基)吡啶 生成 (1 R)-2-[(4-aminophenethyl)amino]-1-(3-pyridinyl)-1-ethanol
  参考文献：
  名称：

  Azolidines as beta-3 adrenergic receptor agonists

  摘要：

  本发明提供了具有以下结构式的I号化合物的药物或药用盐，其中A、X、Y、Z、W、R1、R2、R3、R4、R5和R6的定义如前所述。这些化合物可用于治疗或抑制与胰岛素抵抗或高血糖（通常与肥胖或葡萄糖不耐受有关）相关的代谢紊乱、动脉粥样硬化、胃肠疾病、神经源性炎症、青光眼、眼压增高和频繁排尿，特别是在治疗或抑制2型糖尿病方面特别有用。

  公开号：

  US20020032222A1

文献信息

• Substituted sulfonamides as selective .beta..sub.3 agonists for the
  申请人：Merck & Co., Inc.

  公开号：US05561142A1

  公开（公告）日：1996-10-01

  Substituted sulfonamides are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.

  取代磺酰胺是具有极少量β1和β2肾上腺素受体活性的选择性β3肾上腺素受体激动剂，因此这些化合物能够增加细胞的脂解和能量消耗。因此，这些化合物在治疗II型糖尿病和肥胖症方面具有强效活性。这些化合物也可用于降低甘油三酯水平和胆固醇水平，或提高高密度脂蛋白水平，或减少肠道运动性。此外，这些化合物也可用于减少神经源性炎症或作为抗抑郁剂。这些化合物是通过将氨基烷基苯磺酰胺与适当取代的环氧化物偶联制备而成。该发明还揭示了在治疗糖尿病和肥胖症以及降低甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或增加肠道运动性方面使用这些化合物的组合物和方法。
• Thiazole benzenesulfonamides as .beta.3 agonists for treatment of
  申请人：Merck & Co., Inc.

  公开号：US06011048A1

  公开（公告）日：2000-01-04

  Thiazole substituted benzenesulfonamides are .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.

  噻唑取代的苯磺酰胺是β3肾上腺素受体激动剂，其β1和β2肾上腺素受体活性极低，因此这些化合物能够增加细胞内的脂解和能量消耗。因此，这些化合物在治疗II型糖尿病和肥胖症方面具有强效活性。这些化合物还可以用于降低甘油三酯水平和胆固醇水平，或提高高密度脂蛋白水平，或减少肠道蠕动。此外，这些化合物还可以用于减少神经源性炎症或作为抗抑郁剂。这些化合物是通过将氨基烷基苯磺酰胺与适当取代的环氧化物偶联制备而成。本文还公开了在治疗糖尿病和肥胖症以及降低甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或减少肠道蠕动方面使用这些化合物的组合物和方法。
• Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective β3 adrenergic receptor agonist antiobesity agents
  作者：Tesfaye Biftu、Dennis D Feng、Gui-Bai Liang、Howard Kuo、Xiaoxia Qian、Elizabeth M Naylor、Vincent J Colandrea、Mari R Candelore、Margaret A Cascieri、Lawrence F Colwell、Michael J Forrest、Gary J Hom、D.Euan MacIntyre、Ralph A Stearns、Catherine D Strader、Matthew J Wyvratt、Michael H Fisher、Ann E Weber

  DOI：10.1016/s0960-894x(00)00268-7

  日期：2000.7

  Benzyl and phenoxymethylene substituted oxadiazoles are potent and orally bioavailable beta(3) adrenergic receptor (AR) agonists. The 4-trifluormethoxy substituted 5-benzyl oxadiazole 5f has an EC50 of 8 nM in the beta(3) AR agonist assay with 100-fold selectivity over beta(1) and beta(2) AR binding inhibition activity. Its oral bioavailability in dogs is 30 +/- 4%, with a half-life of 3.8 +/- 0.4 h. In the anesthetized rhesus, 5f evoked a dose-dependent glycerolemia (ED50Gly = 0.15 mg/kg): Under these conditions a heart rate increase of 15% was observed at a dose level of 10 mg/kg. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.
• US6465501B2
  申请人：——

  公开号：US6465501B2

  公开（公告）日：2002-10-15
• US6569873B2
  申请人：——

  公开号：US6569873B2

  公开（公告）日：2003-05-27